ReviewArthritis & rheumatology (Hoboken, N.J.)2018
Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?
Review in Arthritis & rheumatology (Hoboken, N.J.), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 67 citations in OpenAlex.
- Recurrent ischemic strokes with normal inflammatory markers: when tests mislead.Acta neurologica Belgica · 2026Article
- Whole-body Dynamic [18F]FDG-PET/CT in Giant Cell Arteritis and Polymyalgia Rheumatica.Clinical nuclear medicine · 2026Article
- Characteristics of patients with major relapse in giant cell arteritis: a multicenter case-control study.Clinical rheumatology · 2026Article
- 18F-FDG-PET/CT Scan for Detection of Large Vessel Involvement in Giant Cell Arteritis: Arteser Spanish Registry.Journal of clinical medicine · 2024Article
- Estimating overdiagnosis in giant cell arteritis diagnostic pathways using genetic data: genetic association study.Rheumatology (Oxford, England) · 2024Article
- The spectrum of giant cell arteritis through a rheumatology lens.Eye (London, England) · 2024Review
- Multimodality imaging to assess diagnosis and evaluate complications of large vesselarteritis.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2024Review
- Review
- Disease stratification in GCA and PMR: state of the art and future perspectives.Nature reviews. Rheumatology · 2023Review
- Giant-cell arteritis related strokes: scoping review of mechanisms and rethinking treatment strategy?Frontiers in neurology · 2023Article
- Article
- Biomarkers in the era of targeted therapy in giant cell arteritis and polymyalgia rheumatica: is it possible to replace acute-phase reactants?Frontiers in immunology · 2023Review
- Vasculitis distribution and clinical characteristics in giant cell arteritis: a retrospective study using the new 2022 ACR/EULAR classification criteria.Frontiers in medicine · 2023Article
- Observational
- Angiopoietin-2/-1 ratios and MMP-3 levels as an early warning sign for the presence of giant cell arteritis in patients with polymyalgia rheumatica.Arthritis research & therapy · 2022Article
- Review
- Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica.Frontiers in medicine · 2022Review
- Semi-Quantitative and Quantitative [Diagnostics (Basel, Switzerland) · 2021Review
- Functionally Heterogenous Macrophage Subsets in the Pathogenesis of Giant Cell Arteritis: Novel Targets for Disease Monitoring and Treatment.Journal of clinical medicine · 2021Review
- Patient perceptions of health-related quality of life in giant cell arteritis: international development of a disease-specific patient-reported outcome measure.Rheumatology (Oxford, England) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Giant cell arteritis (GCA) is an autoimmune vasculitis affecting large and medium-sized arteries. Ample evidence indicates that GCA is a heterogeneous disease in terms of symptoms, immune pathology, and response to treatment. In the current review, we discuss the evidence for disease subsets in GCA. We describe clinical and immunologic characteristics that may impact the risk of cranial ischemic symptoms, relapse rates, and long-term glucocorticoid requirements in patients with GCA. In addition, we discuss both proven and putative immunologic targets for therapy in patients with GCA who have an unfavorable prognosis. Finally, we provide recommendations for further research on disease subsets in GCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.